EGFR and lung carcinoma: However, further studies with different EGFR-TKIs (e.g. erlotinib or afatinib) and EGFR-TKI sensitive lung cancer cells are still advocated to elucidate further the underlying interaction mechanism of EGFR-TKIs and statins.